FDA approves new eczema drug Dupixent - FDA Press Releases

The U.S. Food and Drug Administration today approved Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema (atopic dermatitis). Dupixent is intended for patients whose eczema is not controlled adequately by topical therapies, or those for whom topical therapies are not advisable. Dupixent can be used with or without topical corticosteroids.

from Food and Drug Administration--Press Releases http://ift.tt/2o2oahf
via IFTTT